Healthcare · Biotechnology
Price
$0.58
Market Cap
$53.3M
Employees
15
Beta
1.61
Avg Volume
1,419,850
CEO
Martin A. Lehr
Business Description
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Business History
Price Overview
Last updated: Jun 27, 2026 11:06am (just now)$0.58
+0.02 (+3.57%)
Day Range
$0.56 – $0.62
52-Week Range
$0.55 – $3.62
50-Day MA
$1.97
200-Day MA
$1.78
Volume
14,801,894.00
Analyst Price Targets
Low
$4.50
Consensus
$5.25
High
$6.00
(3 analysts)
Share Structure
Outstanding
91,879,177.00
Float
64,658,700.00
Free Float
70.4%
Normal free float
— 70.4% of shares trade freely, ~29.6% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-1.53
Stock Price: $0.58
EPS (Diluted): -0.38
EPS (Diluted): -0.38
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.31
Stock Price: $0.58
Total Equity: $60.47M
Shares: 95,185,683
Total Equity: $60.47M
Shares: 95,185,683
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.02
Market Cap: $53.29M
Total Debt: $0.00
Cash: $66.00M
EBITDA: -$36.11M
Total Debt: $0.00
Cash: $66.00M
EBITDA: -$36.11M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$74.0M
Market Cap: $53.29M
Total Debt: $0.00
Cash: $66.00M
Total Debt: $0.00
Cash: $66.00M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $0.58
Revenue: $0.00
Shares: 95,185,683
Revenue: $0.00
Shares: 95,185,683
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$39.70M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$36.12M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-60.0%
Net Income: -$36.12M
Total Equity: $60.47M
Total Equity: $60.47M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-82.9%
Operating Income: -$39.70M
Tax Rate: 0.0%
Equity: $60.47M
Total Debt: $0.00
Cash: $66.00M
Tax Rate: 0.0%
Equity: $60.47M
Total Debt: $0.00
Cash: $66.00M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
8.52
Current Assets: $68.35M
Current Liabilities: $8.02M
Current Liabilities: $8.02M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $60.47M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $60.47M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 95,185,683
Shares: 95,185,683
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.64
Total Equity: $60.47M
Shares: 95,185,683
Shares: 95,185,683
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.28
Operating CF: -$26.39M
CapEx: -$33,948
Shares: 95,185,683
CapEx: -$33,948
Shares: 95,185,683
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.58
Stock Price: $0.58
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$36.12M
Net Income: -$36.12M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CNTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 8:47am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | $10.5M | $15.4M | $25.1M | $29.9M | $39.7M |
| Operating Income | -$10.5M | -$15.4M | -$25.1M | -$29.9M | -$39.7M |
| Net Income | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
| EBITDA | -$7.4M | -$14.9M | -$24.0M | -$26.7M | -$36.1M |
| EPS | $-3.69 | $-0.93 | $-1.50 | $-0.46 | $-0.38 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 8:47am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $49.6M | $35.5M | $14.4M | $94.4M | $66.0M |
| Total Current Assets | $51.3M | $37.9M | $16.0M | $97.9M | $68.4M |
| Total Assets | $51.3M | $38.0M | $16.1M | $98.1M | $68.5M |
| Current Liabilities | $3.0M | $3.2M | $4.2M | $2.7M | $8.0M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.0M | $3.2M | $4.2M | $2.9M | $8.0M |
| Total Equity | $48.3M | $34.8M | $11.9M | $95.3M | $60.5M |
| Retained Earnings | -$29.3M | -$44.1M | -$68.1M | -$94.8M | -$130.9M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 8:47am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$8.8M | -$13.5M | -$21.0M | -$14.6M | -$26.4M |
| Capital Expenditure | $-250,000 | $-536,836 | $0 | -$14.8M | $-33,948 |
| Free Cash Flow | -$9.0M | -$14.1M | -$21.0M | -$29.3M | -$26.4M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $49.3M | -$14.1M | -$21.0M | $80.0M | -$28.4M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 11:06am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue | $0 |
$2.5M $2.5M – $2.5M
|
$10.6M $10.6M – $10.6M
|
$32.4M $32.4M – $32.4M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$49.9M -$51.8M – -$25.4M
|
-$65.0M -$74.1M – -$25.7M
|
-$43.8M -$43.8M – -$43.8M
|
-$35.9M -$35.9M – -$35.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 8:47am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -46.1% | -63.0% | -19.3% | -32.7% |
| Net Income Growth | -41.9% | -61.5% | -11.5% | -35.2% |
| EBITDA Growth | -99.9% | -61.1% | -11.5% | -35.2% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-24 | Pasternak Andy | A-Award | 45,000.00 | $0.58 | $25,920 |
| 2026-06-24 | Stacey Jennifer Evans | A-Award | 45,000.00 | $0.58 | $25,920 |
| 2026-06-24 | West Linda | A-Award | 45,000.00 | $0.58 | $25,920 |
| 2026-06-24 | Smith Karen L. | A-Award | 45,000.00 | $0.58 | $25,920 |
| 2026-06-24 | Walker Luke Nathaniel | A-Award | 45,000.00 | $0.58 | $25,920 |
| 2026-06-24 | Kantoff Philip W. | A-Award | 45,000.00 | $0.58 | $25,920 |
| 2026-02-19 | Levit Alex C. | A-Award | 270,000.00 | $2.32 | $626,400 |
| 2026-02-19 | Minai-Azary Jennifer Lynn | A-Award | 275,000.00 | $2.32 | $638,000 |
| 2026-02-19 | Chagin Karen Deborah | A-Award | 290,000.00 | $2.32 | $672,800 |
| 2026-02-19 | Lehr Martin A. | A-Award | 815,000.00 | $2.32 | $1.9M |
| 2025-06-12 | Pasternak Andy | A-Award | 138,900.00 | $0.65 | $90,702 |
| 2025-06-12 | Kantoff Philip W. | A-Award | 123,500.00 | $0.65 | $80,646 |
| 2025-06-12 | Smith Karen L. | A-Award | 123,500.00 | $0.65 | $80,646 |
| 2025-06-12 | Stacey Jennifer Evans | A-Award | 123,500.00 | $0.65 | $80,646 |
| 2025-06-12 | Walker Luke Nathaniel | A-Award | 123,500.00 | $0.65 | $80,646 |
| 2025-06-12 | West Linda | A-Award | 123,500.00 | $0.65 | $80,646 |
| 2025-06-09 | Lehr Martin A. | P-Purchase | 100,000.00 | $0.70 | $70,080 |
| 2025-06-06 | Levit Alex C. | P-Purchase | 20,000.00 | $0.58 | $11,520 |
| 2025-06-06 | Minai-Azary Jennifer Lynn | P-Purchase | 40,010.00 | $0.64 | $25,486 |
| 2025-06-09 | Chagin Karen Deborah | A-Award | 153,000.00 | $0.70 | $107,559 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CNTX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CNTX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30